Table 5 Types of Nonimmediate Reactions Commonly Tested Using LTT
| Â | Europe, n (%) | Asia Pacific, n (%) | North America, n (%) | Latin America, n (%) | Africa Middle East, n (%) | Region Not Specified, n (%) | Total (n = 32), n (%) |
|---|---|---|---|---|---|---|---|
DIHS | 16 (50.0) | 1 (3.1) | 1 (3.1) | 2 (6.3) | 1 (3.1) | 0 (0.0) | 21 (65.6) |
SJS | 14 (43.8) | 1 (3.1) | 2 (6.3) | 0 (0.0) | 0 (0.0) | 4 (12.5) | 21 (65.6) |
Maculopapular exanthema | 11 (34.3) | 1 (3.1) | 2 (6.3) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 15 (46.9) |
AGEP | 14 (43.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 15 (46.9) |
TEN | 11 (34.3) | 1 (3.1) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 2 (6.3) | 15 (46.9) |
Fixed drug eruption | 7 (21.9) | 2 (6.3) | 1 (3.1) | 1 (3.1) | 1 (3.1) | 1 (3.1) | 13 (40.6) |
Immunbullous eruptions | 9 (28.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 10 (31.3) |
Vasculitis | 6 (18.8) | 1 (3.1) | 0 (0.0) | 1 (3.1) | 1 (3.1) | 0 (0.0) | 9 (28.1) |
Hepatitis | 4 (12.5) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (15.6) |
Blood dyscracias | 2 (6.3) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (9.4) |
Interstitial nephritis | 1 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.1) |